CURE MULTIPLE MYELOMA CORPORATION (EIN 474309020) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2015

Legal Domicile

Principal Officer

HELDA ZORA

Phone

2484496663

Tax Period

2023-01-01 to 2023-12-31

CURE MULTIPLE MYELOMA CORPORATION, founded in 2015, is a small nonprofit in the Diseases & Disorders sector that reported $215K in total revenue in fiscal year 2023. Revenue grew 18% year-over-year, indicating healthy expansion. Expenses of $295K exceeded revenue, resulting in a 37% operating deficit.

Mission

TO RAISE FUNDS FOR MEDICAL RESEARCH FOR THE TREATMENT OF MULTIPLE MYELOMA.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $214,105

Program Service Revenue $0

Investment Income $555

Other Revenue $0

TOTAL REVENUE $214,660

Expense Breakdown

Grants Paid $200,000

Salaries & Benefits $0

Fundraising Expenses $93,855

Program Expenses $201,281

Other Expenses $54,177

TOTAL EXPENSES $295,136

Year-over-Year Comparison

	2023	2022	Change
Revenue	$214,660	$181,255	+0.2%
Expenses	$295,136	$204,746	+0.4%
Net Income	$-80,476	$-23,491	+2.4%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
SIDNEY MOSS	PRESIDENT	N/A	Officer Director	$0	$0	$0
HELDA ZORA	TREASURER/SE	N/A	Officer	$0	$0	$0
BERRY GRANT	DIRECTOR	N/A	Director	$0	$0	$0
RON GARDHOUSE	DIRECTOR	N/A	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$214,660	$295,136	$28,188	$-80,476
2022	$181,255	$204,746	$108,664	$-23,491
2021	$186,482	$151,955	$132,155	$34,527
2020	$106,647	$24,292	$97,628	$82,355
2019	$187,540	$194,544	$15,298	$-7,004
2018	$161,539	$154,063	$22,277	$7,476

CURE MULTIPLE MYELOMA CORPORATION